

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Mouse Anti-CD3 Monoclonal Antibody, Allophycocyanin Conjugated, Clone UCHT1

RRID:AB_398591

Type: Antibody

Proper Citation

BD Biosciences Cat# 555335, RRID:AB_398591

Antibody Information

URL: http://antibodyregistry.org/AB_398591

Proper Citation: BD Biosciences Cat# 555335, RRID:AB_398591

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD3 Monoclonal Antibody, Allophycocyanin Conjugated, Clone UCHT1

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: UCHT1

Antibody ID: AB_398591

Vendor: BD Biosciences

Catalog Number: 555335

Record Creation Time: 20250820T071041+0000

Record Last Update: 20250821T014605+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD3 Monoclonal Antibody, Allophycocyanin Conjugated, Clone UCHT1.

No alerts have been found for Mouse Anti-CD3 Monoclonal Antibody, Allophycocyanin Conjugated, Clone UCHT1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Laheurte C, et al. (2025) UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. Cell reports. Medicine, 6(7), 102196.

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. Cell reports. Medicine, 6(6), 102157.

Hollands CG, et al. (2024) Identification of cells of leukemic stem cell origin with non-canonical regenerative properties. Cell reports. Medicine, 5(4), 101485.

Valeri E, et al. (2024) Removal of innate immune barriers allows efficient transduction of quiescent human hematopoietic stem cells. Molecular therapy : the journal of the American Society of Gene Therapy, 32(1), 124.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Manesia JK, et al. (2023) AA2P-mediated DNA demethylation synergizes with stem cell agonists to promote expansion of hematopoietic stem cells. Cell reports methods, 3(12), 100663.

Omer-Javed A, et al. (2022) Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell, 185(13), 2248.

Gneo L, et al. (2022) TGF- β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. Cancer immunology, immunotherapy : CII, 71(7), 1583.

Takayama N, et al. (2021) The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. Cell stem cell, 28(3), 488.

Loo Yau H, et al. (2021) DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. *Molecular cell*, 81(7), 1469.

Mian SA, et al. (2021) Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. *Blood cancer discovery*, 2(2), 135.

Ferrari S, et al. (2021) BAR-Seq clonal tracking of gene-edited cells. *Nature protocols*, 16(6), 2991.

Arriga R, et al. (2020) CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. *International journal of cancer*, 146(9), 2531.

Petrillo C, et al. (2018) Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. *Cell stem cell*, 23(6), 820.

Kumar D, et al. (2018) Generation of three spinocerebellar ataxia type-12 patients derived induced pluripotent stem cell lines (IGiBi002-A, IGiBi003-A and IGiBi004-A). *Stem cell research*, 31, 216.

Boyd AL, et al. (2018) Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. *Cancer cell*, 34(3), 483.

Benoit YD, et al. (2017) Sam68 Allows Selective Targeting of Human Cancer Stem Cells. *Cell chemical biology*, 24(7), 833.